Retrophin (OTCQB: RTRX), a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that Martin Shkreli, Founder & Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference, which is being held February 11-12 in New York, NY. Shkreli will provide corporate updates and discuss upcoming clinical milestones, including enrollment in a potentially pivotal Phase II clinical trial of Retrophin’s lead compound, RE-021.
